Cover Image
Market Research Report
Product code 
1056100

Europe Insulin Drugs and Glucagon-like Peptide 1 (Glp-1) Receptor Agonist Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Published: | Mordor Intelligence Pvt Ltd | 181 Pages | Delivery time: 2-3 business days

Price

Back to Top
Europe Insulin Drugs and Glucagon-like Peptide 1 (Glp-1) Receptor Agonist Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
Published: January 17, 2022
Mordor Intelligence Pvt Ltd
Content info: 181 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

Diabetes is a chronic, life-threatening disease with no known cure. While Type 1 diabetes is caused by an immune system malfunction, Type-2 diabetes is linked to a sedentary lifestyle, which results in the development of inherent resistance to insulin. The factors leading to an increasing number of reported cases of diabetes can be segmented into individual-level risk factors, environmental risk factors, the evolution of the disease, detection effect, and global changes. Diabetes is associated with many health complications. People with diabetes have a 300% increased risk of being hospitalized compared to those without diabetes, and, thus, they incur more healthcare expenses than non-diabetic people.

Each drug is unique in the way it works in helping patients with diabetes to keep their condition under control. Certain drugs have similar actions, and they are grouped in the same class. They can also be classified in the way they are administered, with some medicines taken orally and others injected directly into the blood (insulin and GLP-1).

Byetta was the first GLP-1 that received approval in 2005. The glucagon-like peptide receptor agonist is administered subcutaneously and is used by Type 2 diabetes patients to control their blood glucose levels.

Key Market Trends

Increasing Diabetes Population in Europe

The rate of newly diagnosed cases of Type 1 and Type 2 diabetes has been increasing among the young population in Europe. The prevalence of diabetes among all age groups in the European region is increasing, mainly due to obesity, unhealthy diet, and physical inactivity. The prevalence of autoimmune Type 1 diabetes is also increasing in Europe.

As per sources, Europe has the highest number of children diagnosed with Type 1 diabetes. Though the treatment of Type 2 patients is initiated with oral drugs, insulin may also be required when glucose levels are not well controlled due to an unhealthy lifestyle. Thus, the demand for insulin also exists among Type 2 diabetes patients.

The rapidly increasing incidence and prevalence of diabetes patients and healthcare expenditure in developed countries are driving the usage of insulin drugs and GLP-1 receptor agonist drugs.

Germany Held the Highest Market Share in 2020

The German market is vast and is expected to grow at a high rate during the forecast period. Due to the increasing diabetes population in Germany, the diabetes care devices market is anticipated to grow during the forecast period. Currently, the number of people diagnosed with diabetes in Germany is about 8.03 million, which is expected to increase to more than 8.25 million by 2026.

Pharmaceutical manufacturers in the country, including Novo Nordisk, have assured that there is no current impact of COVID-19 on their supply chain. Furthermore, companies are regularly monitoring their supply chain to better assess the situation and act proactively, in order to ensure minimal or no disruption in the availability of insulin drugs for the diabetes population in the country.

Insulin drug pricing is a major concern in many countries, and Germany is not an exception. The German government regulates the prices of drugs, and thus, pharmaceutical companies are focusing on pricing the products at minimal rates.

Competitive Landscape

The insulin drugs and GLP-1 receptor agonist market is largely consolidated in nature, with the presence of leading companies, like Sanofi, Novo Nordisk, and Eli Lilly. They account for more than 80% of the supply in Europe. All these companies have established their brands in the market. However, due to intense competition in the local markets for insulin, consumer penetration for their products must be achieved through constant work and effort.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 71970

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET INSIGHTS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 By Type

  • 5.1 GLP-1 Receptor Agonists (Value and Volume, 2016-2026)
    • 5.1.1 Exenatide
      • 5.1.1.1 Byetta
      • 5.1.1.2 Bydureon
    • 5.1.2 Liraglutide (Victoza)
    • 5.1.3 Lixisenatide (Lyxumia)
    • 5.1.4 Dulaglutide (Trulicity)
    • 5.1.5 Semaglutide (Ozempic)
  • 5.2 Insulin Drugs (Value and Volume, 2016-2026)
    • 5.2.1 Basal or Long-acting Insulins
      • 5.2.1.1 Lantus (Insulin glargine)
      • 5.2.1.2 Levemir (Insulin detemir)
      • 5.2.1.3 Toujeo (Insulin glargine)
      • 5.2.1.4 Tresiba (Insulin degludec)
      • 5.2.1.5 Basaglar (Insulin glargine)
    • 5.2.2 Bolus or Fast-acting Insulins
      • 5.2.2.1 NovoRapid/Novolog (Insulin aspart)
      • 5.2.2.2 Humalog (Insulin lispro)
      • 5.2.2.3 Apidra (Insulin glulisine)
      • 5.2.2.4 FIASP (Insulin aspart)
      • 5.2.2.5 Admelog (Insulin lispro)
    • 5.2.3 Traditional Human Insulins
      • 5.2.3.1 Novolin/Actrapid/Insulatard
      • 5.2.3.2 Humulin
      • 5.2.3.3 Insuman
    • 5.2.4 Combination Insulins
      • 5.2.4.1 NovoMix (Biphasic Insulin aspart)
      • 5.2.4.2 Ryzodeg (Insulin degludec/Insulin aspart)
      • 5.2.4.3 Xultophy (Insulin degludec/Liraglutide)
      • 5.2.4.4 Soliqua/Suliqua (Insulin glargine/ Lixisenatide)
    • 5.2.5 Biosimilar Insulins
      • 5.2.5.1 Insulin Glargine Biosimilars
      • 5.2.5.2 Human Insulin Biosimilars

6 By Geography (Value and Volume, 2016-2026, and By Type)

  • 6.1 United Kingdom
  • 6.2 Germany
  • 6.3 France
  • 6.4 Italy
  • 6.5 Spain
  • 6.6 Russia
  • 6.7 Rest of Europe

7 MARKET INDICATORS BY COUNTRY

  • 7.1 Type -1 Diabetes Population (2016-2026)
  • 7.2 Type -2 Diabetes Population (2016-2026)

8 COMPETITIVE LANDSCAPE

  • 8.1 Company Profiles
    • 8.1.1 Novo Nordisk
    • 8.1.2 Sanofi
    • 8.1.3 Eli Lilly
    • 8.1.4 AstraZeneca
    • 8.1.5 Biocon
    • 8.1.6 Pfizer
    • 8.1.7 Wockhardt
    • 8.1.8 Julphar
    • 8.1.9 Exir
    • 8.1.10 Sedico
  • 8.2 Company Share Analysis

9 GLP-1 USAGE ANALYSIS

10 MARKET OPPORTUNITES AND FUTURE TRENDS